These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 16203785

  • 1. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
    Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6933-43. PubMed ID: 16203785
    [Abstract] [Full Text] [Related]

  • 2. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
    Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M, Itoh K.
    Clin Cancer Res; 2004 Feb 01; 10(3):1112-20. PubMed ID: 14871991
    [Abstract] [Full Text] [Related]

  • 3. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
    Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M.
    Br J Cancer; 2007 Dec 17; 97(12):1648-54. PubMed ID: 18043580
    [Abstract] [Full Text] [Related]

  • 4. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
    Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.
    Int Immunopharmacol; 2015 May 17; 26(1):133-8. PubMed ID: 25819666
    [Abstract] [Full Text] [Related]

  • 5. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
    Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M.
    J Immunother; 2007 Apr 17; 30(3):274-81. PubMed ID: 17414318
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K.
    Oncol Rep; 2004 Sep 17; 12(3):601-7. PubMed ID: 15289844
    [Abstract] [Full Text] [Related]

  • 9. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
    Matsueda S, Yamada A, Takao Y, Tamura M, Komatsu N, Yutani S, Ide T, Sata M, Itoh K.
    Cancer Immunol Immunother; 2007 Sep 17; 56(9):1359-66. PubMed ID: 17265020
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.
    Clin Cancer Res; 2002 Dec 17; 8(12):3885-92. PubMed ID: 12473604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A.
    Int J Cancer; 1998 Nov 09; 78(4):518-24. PubMed ID: 9797143
    [Abstract] [Full Text] [Related]

  • 15. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.
    Clin Cancer Res; 2003 Aug 15; 9(9):3260-71. PubMed ID: 12960111
    [Abstract] [Full Text] [Related]

  • 16. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K, Kono K, Southwood S, Fikes J, Takahashi A, Miyagawa N, Sugai H, Fujii H.
    Cancer Immunol Immunother; 2006 Nov 15; 55(11):1358-66. PubMed ID: 16435129
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.